HB140 makes extensive changes to Kentucky law governing blood donation, blood testing, transfusion, and related health coverage. It expands the statutory definitions in KRS Chapter 214 and adds new donor screening, labeling, storage, and consent requirements for blood establishments, health facilities, health services, and health care providers. The bill requires blood to be tested for HIV and other blood-borne communicable diseases, and it adds proposed testing and disclosure requirements for spike proteins, SARS-CoV-2 nucleocapsid antibodies, and synthetic mRNA, but only upon approval of an FDA test for mRNA. It also adds new rules for autologous and directed donations, emergency use of untested blood, and recordkeeping for donor and transfusion information.
The bill also creates several new policy mandates outside the blood-donation statutes. It prohibits state agencies from maintaining lists of citizens’ vaccination status, requires hospitals to invest in blood transfusion prevention strategies and create bloodless medicine and surgery task forces, and requires health benefit plans, Medicaid, and certain public employee plans to cover directed and autologous blood transfusions. It further amends state employee and postsecondary institution health plan statutes to incorporate those coverage requirements, with an effective date for those insurance-related provisions of January 1, 2026. The bill includes implementation and federal-approval provisions for Medicaid-related changes and requires facilities to have infrastructure in place to store and label blood within 90 days of enactment.
In terms of legal impact, HB140 would significantly revise KRS 214.450 to 214.466 and related insurance and public employee health statutes. It would impose new duties on blood establishments regarding donor screening, labeling, testing, disclosure, and refusal of donations from persons with specified risk factors or certain medical treatments. It would also create new obligations for hospitals and insurers, including coverage mandates for directed and autologous transfusions and compliance requirements for Medicaid and public employee health plans. The bill’s scope reaches multiple chapters of Kentucky law, including public health, Medicaid, state employee benefits, and postsecondary institution health plans.
The general sentiment reflected by the bill text itself is strongly precautionary and restrictive, emphasizing blood safety, donor exclusion, and patient consent. Because there are no committee transcripts or recorded votes provided, there is no documented public debate or vote history in the materials to indicate support or opposition. The structure of the bill suggests an intent to impose broad new safeguards and reporting requirements rather than to make incremental changes.
The main points of contention likely center on the bill’s proposed testing and disclosure requirements for spike proteins, SARS-CoV-2 antibodies, and synthetic mRNA, as well as the restrictions on donors who have received genetically engineered blood products or experimental therapies. Another likely area of dispute is the requirement that patients be informed and consent to receiving blood with mRNA present, along with the prohibition on state agencies keeping vaccination-status lists. These provisions could raise concerns about medical accuracy, federal preemption, administrative feasibility, and the burden placed on blood banks, hospitals, and insurers.
HB140 would amend Kentucky’s blood-donation and transfusion laws in KRS Chapter 214 by adding new donor screening, testing, labeling, consent, and recordkeeping requirements, while also creating new duties for hospitals and health plans. It would require blood establishments and transfusion providers to comply with expanded testing and disclosure rules, prohibit certain donors from donating blood, and require destruction of improperly labeled blood. It would also mandate coverage for directed and autologous transfusions in health benefit plans, Medicaid, and public employee plans, and add new hospital and state-agency requirements affecting bloodless medicine and vaccination-status records.
No committee transcripts or votes were provided, so there is no recorded legislative debate or roll-call history to measure support or opposition. Based on the bill text, the measure is framed in a highly protective, safety-focused way, with strong restrictions on blood donation and transfusion practices. The overall tone is assertive and regulatory, suggesting proponents are prioritizing precaution and patient control over blood-related medical decisions.
The most notable likely controversies are the bill’s requirements to test for and disclose spike proteins, SARS-CoV-2 nucleocapsid antibodies, and synthetic mRNA, and its restrictions on donors who have received genetically engineered blood products or experimental therapies. Critics may question the scientific basis, operational feasibility, and whether these provisions conflict with federal blood-bank standards or FDA authority. The prohibition on state agencies maintaining vaccination-status lists and the patient-consent rules for blood with mRNA present may also be contentious because they implicate privacy, public health administration, and medical practice standards.